GOSS vs GTBP

Gossamer Bio, Inc. vs GT Biopharma, Inc. — Valuation Comparison 2026

GOSS

Biotechnology
Gossamer Bio, Inc.
Quality
5.3
out of 10
Value Trap
24
SAFE
Price
$0.21
Last close
Models
7/13
Active
VS

GTBP

Biotechnology
GT Biopharma, Inc.
Quality
3.5
out of 10
Value Trap
24
SAFE
Price
$0.45
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType GOSS Fair ValueGOSS Upside GTBP Fair ValueGTBP Upside
Bayesian DCF Intrinsic $0.14 -31.7% $0.25 -42.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $0.06 -83.6%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.08 -62.3% $1.74 +289.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GOSS vs GTBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GOSS vs GTBP — Which Stock Is More Undervalued?

GOSS scores higher with a 5.3/10 quality rating vs GTBP's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Gossamer Bio, Inc. (GOSS) and GT Biopharma, Inc. (GTBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GOSS currently trades at $0.21 with a QOC of 5.3/10, while GTBP trades at $0.45 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).